[Delirium during withdrawal of venlafaxine].
A 35-year-old man with anxiety and depression who was treated with venlafaxine, 300 mg a day, developed severe withdrawal symptoms in the form of a delirium during gradual tapering of the dosage. The symptoms resolved when the dosage was kept constant and did not recur when the dosage was reduced more gradually. Withdrawal symptoms are common during discontinuation of antidepressants, particularly after prolonged use of agents with a short half-life. The symptoms are usually mild and transient, especially in the case of selective serotonin reuptake inhibitors and venlafaxine. The occurrence of delirium as a result of the withdrawal of venlafaxine has not been reported previously. Even when antidepressants are being withdrawn with care, one should remain alert to the possible development of severe withdrawal symptoms.
van Noorden
M S
MS
Sint Lucas Andreas Ziekenhuis, afd. Psychiatrie, Postbus 9243, 1006 AE Amsterdam.
Vergouwen
A C M
AC
Koerselman
G F
GF
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D003511:Cyclohexanols / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D003693:Delirium / Q000139:chemically induced* / Q000209:etiology; D003863:Depression / Q000188:drug therapy; D004334:Drug Administration Schedule; D006207:Half-Life; D006801:Humans; D008297:Male; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride